Background: Amyotrophic lateral sclerosis is a fatal motor neuron degenerative disease. Most cases are sporadic (SALS), and approximately 10% are familial (FALS) among which over 20% are linked to the SOD1 mutation. Both SALS and FALS have been associated with retrograde axonal transport defects. Kinesins (KIFs) are motor proteins involved mainly in anterograde transport; however, some also participate in retrograde transport. Objective: The purpose of the study was to investigate and compare the expression of kinesins involved in anterograde (KIF5A, 5C) and retrograde (KIFC3/C2) axonal transport in SALS in humans and FALS in mice with the hSOD1G93A mutation. Methods: The studies were conducted on various parts of the CNS from autopsy specimens of SALS patients, and transgenic mice at presymptomatic and symptomatic stages using real-time quantitative PCR and reverse-transcription PCR. Results: All KIF expression in the motor cortex of individual SALS subjects was higher than in the adjacent sensory cortex, in contrast to the expression in control brains. It was also significantly higher in the frontal cortex of symptomatic but not presymptomatic mice compared to wild-type controls. However, the mean KIF expression in the SALS motor and sensory cortexes was lower than in control cortexes. To a lesser extent the decrease in KIF mean expression also occurred in human but not in mouse ALS spinal cords and in both human and mouse cerebella. Conclusion: Disturbances in kinesin expression in the CNS may dysregulate both anterograde and retrograde axonal transports leading to motor neuron degeneration.

Keywords:
Kinesin expression, Neurodegeneration, Sporadic amyotrophic lateral sclerosis, hSOD1G93A mutation, Transgenic mice, Central nervous system
1.
Haverkamp LJ, Appel V, Appel SH: Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995;118:707-719.
2.
Mulder DW, Kurland LT, Offord KP, Beard CM: Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology 1986;36:511-517.
3.
Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al: Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994;264:1772-1775.
4.
Dal Canto MC, Gurney ME: Neuropathological changes in two lines of mice carrying a transgene for mutant human CuZn SOD and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis. Brain Res 1995;676:25-40.
5.
Tu PH, Raju P, Robinson KA, Gurney ME, Trojanowski JQ, Lee VM: Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci USA 1996;93:3155-3160.
6.
El-Kadi AM, Soura V, Hafezparast M: Defective axonal transport in motor neurodisease, J Neurosci Res 2007;85:2557-2566.
7.
Hirokawa N, Noda Y, Tanaka Y, Niwa S: Kinesin superfamily motor proteins and intracellular transport. Nature 2009;10:682-696.
8.
Eschbach J, Dupuis L: Cytoplasmic dynein in neurodegeneration. Pharmacol Ther 2011;130:348-363.
9.
Miki H, Okada Y, Hirikawa N: Analysis of the kinesin superfamily: insights into structure and function. Trends Cell Biol 2005;15:465-476.
10.
Hirokawa N, Tekamura R: Molecular motors in neuronal development, intracellular transport and diseases. Curr Opin Neurol 2004;14:564-573.
11.
Hanlon DW, Yang Z, Goldstein LS: Characterization of KIFC2, a neuronal kinesin superfamily member in mouse. Neuron 1997;18:439-451.
12.
Saito N, Okada Y, Noda Y, Kinoshita Y, Kondo S, Hirokawa N: KIFC2 is a novel neuron-specific C-terminal type kinesin superfamily motor for dendritic transport of multivesicular body-like organelles. Neuron 1997;3:425-438.
13.
Kanai Y, Okada Y, Tanaka Y, Harada A, Terada S. Hirokawa N: KIF5C, a novel neuronal kinesin enriched in motor neurons. J Neurosci 2000;20:6374-6384.
14.
Nangaku M, Sato-Yoshitake R, Okada Y, Noda Y, Tekemura R, Yamazaki H, Hirokawa N: KIF1B, a novel microtubule plus end-directed monomeric motor protein for transport of mitochondria. Cell 1994;79:1209-1220.
15.
Vale RD, Fletterick RJ: The design plan of kinesin motors. Annu Rev Cell Dev Biol 1997;13:745-777.
16.
Hua W, Young EC, Fleming ML, Gelles J: Coupling of kinesin steps to ATP hydrolysis. Nature 1997;388:390-393.
17.
Matsushita M, Yamamoto K, Mitsui K, Kanazawa H: Altered motor activity of alternative splice variations of the mammalian kinesin-3 protein KIF1B. Traffic 2009;10:1647-1654.
18.
Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Floeter MK, Budus K, Drayna D, Oh SJ, Brown RH Jr, Ludlow CL, Fischbeck KH: Mutant dynactin in motor neuron disease. Nat Genet 2003;33:455-456.
19.
Munch C, Sedlmeier R, Meyer T, Homberg V, Sperfeld AD, Kurt A, Prudlo J, Peraus G, Hanemann CO, Stumm G, Ludolph AC: Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology 2004;63:724-726.
20.
Mizuno N, Toba S, Edamatsu M, Watai-Nishii J, Kikkawa M: Dynein and kinesin share an overlapping microtubule-binding site. EMBO J 2004;23:2459-2467.
21.
Brady ST, Pfister KK, Bloom GS: A monoclonal antibody against kinesin inhibits both anterograde and retrograde fast axonal transport in squid axoplasm. Proc Natl Acad Sci USA 1990;87:1061-1065.
22.
Toyoshima I, Sugawara M, Kato K, Wada C, Hirota K, Hasegawa K, Kowa H, Sheetz MP, Masamune O: Kinesin and cytoplasmic dynein in spinal spheroids with motor neuron disease. J Neurol Sci 1998;159:38-44.
23.
Reid E, Kloos M, Ashley-Koch A, Hughes L, Bevan S, Svenson IK, Graham FL, Gaskell PC, Dearlove A, Pericak-Vance MA, Rubinsztein DC, Marchuk DA: A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am J Hum Genet 2002;71:1189-1194.
24.
Ebbing B, Mann K, Starosta A, Jaud J, Schule R, Woehike G: Effect of spastic paraplegia mutations in KIF5A kinesin on transport activity. Hum Mol Genet 2008;17:1245-1252.
25.
Conforti L, Dell'Agnello C, Calvaresi N, Tortarolo M, Giorgini A, Coleman MP, Bendotti C: Kif1Bββisoform is enriched in motor neurons but does not change in a mouse model of amyotrophic lateral sclerosis. J Neurosci Res 2003;71:732-733.
26.
Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
27.
Teuchert M, Fischer D, Schwalenstoecker B, Habisch HJ, Bockers TM, Ludolph AC: A dynein mutation attenuates motor neuron degeneration in SOD1G93A mice. Exp Neurol 2006;198:271-274.
28.
Kuźma-Kozakiewicz M, Usarek E, Ludolph AC, Barańczyk-Kuźma A: Mice with mutation in dynein heavy chain 1 do not share the same tau expression pattern with mice with SOD1-related motor neuron disease. Neurochem Res 2011;36:978-985.
29.
Vershinin M, Brian C, Carter C, Razafsky DS, King SJ, Gross SJ: Multiple-motor based transport and its regulation by tau. Proc Natl Acad Sci USA 2007;104:87-92.
30.
Dixit R, Ross LR, Goldman YE, Holzbaur EL: Differential regulation of dynein and kinesin motor proteins by tau. Science 2008;319:1086-1089.
31.
Andreadis A: Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochim Biophys Acta 2005;1739:91-103.
32.
Mandelkow E, Von Bergen M, Biernat J, Mandelkow EM: Structural principles of tau and Alzheimer paired helical filaments. Brain Pathol 2007;17:83-90.
33.
Brandt R, Leger J, Lee G: Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J Cell Biol 1999;131:1327-1340.
34.
Georgieff IS, Liem RK, Couchie D, Mavilia C, Nunez J, Shelanski ML: Expression of high molecular weight tau in the central and peripheral nervous systems. J Cell Sci 1993;105:729-737.
35.
Usarek E, Kuźma-Kozakiewcz M, Schwalenstöcker B, Kaźmierczak B, Münch C, Ludolph AC, Barańczyk-Kuźma A: Tau isoforms expression in transgenic mouse model of amyotrophic lateral sclerosis. Neurochem Res 2006;31:597-602.
36.
LaPointe NE, Morfini G, Pigino G, Gaisina IN, Kozikowski AP, Binder LI, Brady ST: The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J Neurosci Res 2009;87:440-451.
37.
Dupuis L, de Tapia M, Rene F, Lutz-Bucher B, Gordon JW, Mercken L, Pradier L, Loeffler J-P: Differential screening of mutated SOD1 transgenic mice reveals early up-regulation of a fast axonal transport component in spinal cord motor neurons. Neurobiol Dis 2000;7:274-285.
38.
Agosta F, Chiò A, Cosottini M, De Stefano N, Faleni A, Mascalchi M, Rocca MA, Silani V, Tedeschi G, Filippi M: The present and the future of neuroimaging in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol 2010;31:1769-1777.
39.
Barańczyk-Kuźma A, Usarek E, Kuźma-Kozakiewcz M, Kaźmierczak B, Gajewska B, Schwalenstocker B, Ludolph AC: Age-related changes in tau expression in transgenic mouse model of amyotrophic lateral sclerosis. Neurochem Res 2007;32:415-421.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.